Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...

Eli Lilly says a new starting dose regimen for ... which showed that the modified Kisunla (donanemab) regimen reduced the risk of ARIA-E over 24 weeks to 14% from 24% in the pivotal trial that ...

Lilly cues up filing for amyloid drug donanemab Meanwhile, other developments in Alzheimer's continue apace, with Eli Lilly saying today that it intends to file for approval of amyloid antibody ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...